Requirement of p38 MAPK for a cell-death pathway triggered by vorinostat in MDA-MB-231 human breast cancer cells

Cancer Letters

Volumn 315, Issue 2, 2012, Pages 112-121

  Uehara, Norihisa ^a   Kanematsu, Sayaka ^a   Miki, Hisanori ^a   Yoshizawa, Katsuhiko ^a   Tsubura, Airo ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Breast cancer; Caspase 3; P38 MAPK; Vorinostat

Indexed keywords

CASPASE 3; HISTONE H3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; VORINOSTAT;

ACETYLATION; APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEPHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; HYDROXAMIC ACIDS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84355166524     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.07.032     Document Type: Article

References (43)

1. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
2. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
3. Toyota M., Issa J.P. Epigenetic changes in solid and hematopoietic tumors. Seminars Oncol. 2005, 32:521-530.
4. Halkidou K., Gaughan L., Cook S., Leung H.Y., Neal D.E., Robson C.N. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004, 59:177-189.
5. Choi S.Y., Kim M.J., Kang C.M., Bae S., Cho C.K., Soh J.W., Kim J.H., Kang S., Chung H.Y., Lee Y.S., Lee S.J. Activation of Bak and Bax through c-abl-protein kinase Cdelta-p38 MAPK signaling in response to ionizing radiation in human non-small cell lung cancer cells. J. Biol. Chem. 2006, 281:7049-7059.
6. Wilson A.J., Byun D.S., Popova N., Murray L.B., L'Italien K., Sowa Y., Arango D., Velcich A., Augenlicht L.H., Mariadason J.M. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem. 2006, 281:13548-13558.
7. Zhang Z., Yamashita H., Toyama T., Sugiura H., Ando Y., Mita K., Hamaguchi M., Hara Y., Kobayashi S., Iwase H. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res. Treat. 2005, 94:11-16.
8. Zhang Z., Yamashita H., Toyama T., Sugiura H., Omoto Y., Ando Y., Mita K., Hamaguchi M., Hayashi S., Iwase H. HDAC6 expression is correlated with better survival in breast cancer. Clin. Cancer Res. 2004, 10:6962-6968.
9. Lin R.J., Nagy L., Inoue S., Shao W., Miller W.H., Evans R.M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998, 391:811-814.
10. Wang J., Hoshino T., Redner R.L., Kajigaya S., Liu J.M. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc. Natl. Acad. Sci. USA 1998, 95:10860-10865.
11. Batty N., Malouf G.G., Issa J.P. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett. 2009, 280:192-200.
12. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5:769-784.
13. Marks P.A., Xu W.S. Histone deacetylase inhibitors: potential in cancer therapy. J. Cell Biochem. 2009, 107:600-608.
14. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
15. Richon V.M., Garcia-Vargas J., Hardwick J.S. Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett. 2009, 280:201-210.
16. Lindemann R.K., Newbold A., Whitecross K.F., Cluse L.A., Frew A.J., Ellis L., Williams S., Wiegmans A.P., Dear A.E., Scott C.L., Pellegrini M., Wei A., Richon V.M., Marks P.A., Lowe S.W., Smyth M.J., Johnstone R.W. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc. Natl. Acad. Sci. USA 2007, 104:8071-8076.
17. Xu W., Ngo L., Perez G., Dokmanovic M., Marks P.A. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc. Natl. Acad. Sci. USA 2006, 103:15540-15545.
18. Wada T., Penninger J.M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004, 23:2838-2849.
19. Jung J.W., Cho S.D., Ahn N.S., Yang S.R., Park J.S., Jo E.H., Hwang J.W., Jung J.Y., Kim S.H., Kang K.S., Lee Y.S. Ras/MAP kinase pathways are involved in Ras specific apoptosis induced by sodium butyrate. Cancer Lett. 2005, 225:199-206.
20. Mitchell C., Park M.A., Zhang G., Yacoub A., Curiel D.T., Fisher P.B., Roberts J.D., Grant S., Dent P. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Mol. Cancer Ther. 2007, 6:3101-3112.
21. Portanova P., Russo T., Pellerito O., Calvaruso G., Giuliano M., Vento R., Tesoriere G. The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells. Int. J. Oncol. 2008, 33:325-331.
22. Uehara N., Matsuoka Y., Tsubura A. Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. Mol. Cancer Res. 2008, 6:186-193.
23. Richon V.M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R.A., Marks P.A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA 1998, 95:3003-3007.
24. Burgess A., Ruefli A., Beamish H., Warrener R., Saunders N., Johnstone R., Gabrielli B. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004, 23:6693-6701.
25. Insinga A., Monestiroli S., Ronzoni S., Gelmetti V., Marchesi F., Viale A., Altucci L., Nervi C., Minucci S., Pelicci P.G. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 2005, 11:71-76.
26. Ungerstedt J.S., Sowa Y., Xu W.S., Shao Y., Dokmanovic M., Perez G., Ngo L., Holmgren A., Jiang X., Marks P.A. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 2005, 102:673-678.
27. Huang L., Pardee A.B. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol. Med. 2000, 6:849-866.
28. Cory S., Huang D.C., Adams J.M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003, 22:8590-8607.
29. Rahmani M., Anderson A., Habibi J.R., Crabtree T.R., Mayo M., Harada H., Ferreira-Gonzalez A., Dent P., Grant S. The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood 2009, 114:4507-4516.
30. Willis S.N., Adams J.M. Life in the balance: how BH3-only proteins induce apoptosis. Curr. Opin. Cell Biol. 2005, 17:617-625.
31. Curtin J.F., Cotter T.G. Live and let die: regulatory mechanisms in Fas-mediated apoptosis. Cell Signal 2003, 15:983-992.
32. Bali P., Pranpat M., Swaby R., Fiskus W., Yamaguchi H., Balasis M., Rocha K., Wang H.G., Richon V., Bhalla K. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin. Cancer Res. 2005, 11:6382-6389.
33. Ley R., Balmanno K., Hadfield K., Weston C., Cook S.J. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J. Biol. Chem. 2003, 278:18811-18816.
34. Luciano F., Jacquel A., Colosetti P., Herrant M., Cagnol S., Pages G., Auberger P. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003, 22:6785-6793.
35. Tan J., Zhuang L., Jiang X., Yang K.K., Karuturi K.M., Yu Q. Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity. J. Biol. Chem. 2006, 281:10508-10515.
36. Zhao Y., Tan J., Zhuang L., Jiang X., Liu E.T., Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc. Natl. Acad. Sci. USA 2005, 102:16090-16095.
37. Zhou Q., Shaw P.G., Davidson N.E. Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. Breast Cancer Res. Treat. 2009, 117:443-451.
38. Chen K.C., Liu W.H., Kao P.H., Chang L.S. Calcium-stimulated mitogen-activated protein kinase activation elicits Bcl-xL downregulation and Bak upregulation in notexin-treated human neuroblastoma SK-N-SH cells. J. Cell Physiol. 2010, 222:177-186.
39. Ivanova I.A., Dagnino L. Activation of p38- and CRM1-dependent nuclear export promotes E2F1 degradation during keratinocyte differentiation. Oncogene 2007, 26:1147-1154.
40. Wang Y., Sun L., Xia C., Ye L., Wang B. p38MAPK regulates caspase-3 by binding to caspase-3 in nucleus of human hepatoma Bel-7402 cells during anti-Fas antibody- and actinomycin D-induced apoptosis. Biomed. Pharmacother. 2009, 63:343-350.
41. Gordon L.A., Mulligan K.T., Maxwell-Jones H., Adams M., Walker R.A., Jones J.L. Breast cell invasive potential relates to the myoepithelial phenotype. Int. J. Cancer 2003, 106:8-16.
42. Chen L., Mayer J.A., Krisko T.I., Speers C.W., Wang T., Hilsenbeck S.G., Brown P.H. Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res. 2009, 69:8853-8861.
43. Lee C.K., Wang S., Huang X., Ryder J., Liu B. HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. Cancer Lett. 2010, 296:233-240.